Xilio Therapeutics (XLO) appoints Cheryl R. Blanchard as director

AI Summary

Xilio Therapeutics (XLO) announced the appointment of Cheryl R. Blanchard as a director and chair of the compensation committee. Blanchard brings extensive experience in the biotechnology field, having held multiple executive roles. This change in leadership may influence investor confidence and the company's strategic direction. The impact on Xilo's market performance will depend on future developments related to its clinical programs.